Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies

Clinical Pharmacokinetics

Volumn 47, Issue 4, 2008, Pages 277-284

  Zahr, Noël ^a,c   Amoura, Zahir ^a   Debord, Jean ^b   Hulot, Jean Sébastien ^a   Saint Marcoux, Franck ^b   Marquet, Pierre ^b   Piette, Jean Charles ^a   Lechat, Philippe ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARTMENT MODEL; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 40549127818     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847040-00005     Document Type: Article

References (36)

1. 1. T. Gelder van Y. Meur Le L.M. Shaw 2006 Therapeutic drug monitoring of mycophenolate mofetil in transplantation Ther Drug Monit 28 145 54 16628123 10.1097/01.ftd.0000199358.80013.bd van Gelder T, LeMeur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145–54
2. 2. T. Gelder van L.B. Hilbrands Y. Vanrenterghem 1999 A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation Transplantation 68 261 6 10440399 10.1097/00007890-199907270-00018 van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261–6
3. 3. C. Guellec Le H. Bourgoin M. Buchler 2004 Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients Clin Pharmacokinet 43 253 66 15005639 10.2165/00003088-200443040-00004 LeGuellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet 2004; 43: 253–66
4. 4. H. Chen C. Peng Z. Yu 2007 Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients Clin Pharmacokinet 46 175 85 17253887 10.2165/00003088-200746020-00005 Chen H, Peng C, Yu Z, et al. Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin Pharmacokinet 2007; 46: 175–85
5. 5. T. Pawinski M. Hale M. Korecka 2002 Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus Clin Chem 48 1497 504 12194926 1:CAS:528:DC%2BD38XmslSqur4%3D Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 1497–504
6. 6. Y. Zicheng Z. Weixia C. Hao 2007 Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult patients undergoing liver transplant Ther Drug Monit 29 207 14 17417076 10.1097/FTD.0b013e318040ce0b Zicheng Y, Weixia Z, Hao C, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult patients undergoing liver transplant. Ther Drug Monit 2007; 29: 207–14
7. 7. J. Ng J. Rogosheske J. Barker 2006 A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT) Ther Drug Monit 28 394 401 16778725 10.1097/01.ftd.0000211821.73231.8a 1:CAS:528:DC%2BD28Xls1KhtLs%3D Ng J, Rogosheske J, Barker J, et al. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit 2006; 28: 394–401
8. 8. G. Filler I. Mai 2000 Limited sampling strategy for mycophenolic acid area under the curve Ther Drug Monit 22 169 73 10774628 10.1097/00007691-200004000-00005 1:CAS:528:DC%2BD3cXisl2nur4%3D Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000; 22: 169–73
9. 9. L.T. Weber B. Hoecker V.W. Armstrong 2006 Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients Ther Drug Monit 28 623 31 17038876 10.1097/01.ftd.0000246766.12872.12 1:CAS:528:DC%2BD28XhtVKrtLzE Weber LT, Hoecker B, Armstrong VW, et al. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit 2006; 28: 623–31
10. 10. G. Filler 2004 Abbreviated mycophenolic acid AUC from CO, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy Transpl Int 17 120 5 14749919 1:CAS:528:DC%2BD2cXis1GgtrY%3D Filler G. Abbreviated mycophenolic acid AUC from CO, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int 2004; 17: 120–5
11. 11. C. Monchaud A. Rousseau F. Leger 2003 Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0–12) monitoring in cardiac transplant recipients over the first year post-transplantation Eur J Clin Pharmacol 58 813 20 12698308 1:CAS:528:DC%2BD3sXltFGgu7c%3D Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0–12) monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol 2003; 58: 813–20
12. 12. A. Premaud Y. Meur Le J. Debord 2005 Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods Ther Drug Monit 27 354 61 15905807 10.1097/01.ftd.0000162231.90811.38 1:CAS:528:DC%2BD2MXktlKks78%3D Premaud A, LeMeur Y, Debord J, et al. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 2005; 27: 354–61
13. 13. A.C. Allison E.M. Eugui 2000 Mycophenolate mofetil and its mechanisms of action Immunopharmacology 47 85 118 10878285 10.1016/S0162-3109(00)00188-0 1:CAS:528:DC%2BD3cXktlKkt7o%3D Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85–118
14. 14. G.B. Appel J. Radhakrishnan E.M. Ginzler 2005 Use of mycophenolate mofetil in autoimmune and renal diseases Transplantation 80 2Suppl. S265 71 16251859 10.1097/01.tp.0000186389.19911.9c 1:CAS:528:DC%2BD2MXhtFGhsL7L Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 2005; 80(2 Suppl.): S265–71
15. 15. T.M. Chan F.K. Li C.S. Tang 2000 Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group N Engl J Med 343 1156 62 11036121 10.1056/NEJM200010193431604 1:CAS:528:DC%2BD3cXnsleqs7w%3D Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156–62
16. 16. G. Contreras V. Pardo B. Leclercq 2004 Sequential therapies for proliferative lupus nephritis N Engl J Med 350 971 80 14999109 10.1056/NEJMoa031855 1:CAS:528:DC%2BD2cXhvFGjsrc%3D Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971–80
17. 17. E.M. Ginzler M.A. Dooley C. Aranow 2005 Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis N Engl J Med 353 2219 28 16306519 10.1056/NEJMoa043731 1:CAS:528:DC%2BD2MXht1GrsLbJ Ginzler E.M, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219–28
18. 18. P.J. Smak Gregoor T. Gelder van C.J. Hesse 1999 Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study Nephral Dial Transplant 14 706 8 10.1093/ndt/14.3.706 1:STN:280:DyaK1M3gvVWltA%3D%3D Smak Gregoor PJ, van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephral Dial Transplant 1999; 14: 706–8
19. 19. C.G. Patel M. Harmon R.Y. Gohh 2007 Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus Ther Drug Monit 29 87 95 17304155 10.1097/FTD.0b013e3180318c35 1:CAS:528:DC%2BD2sXhslCmtbY%3D Patel CG, Harmon M, Gohh RY, et al. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus. Ther Drug Monit 2007; 29: 87–95
20. 20. D.A. Hesselink R.M. Hest van R.A. Mathot 2005 Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2 Am J Transplant 5 987 94 15816878 10.1046/j.1600-6143.2005.00779.x 1:CAS:528:DC%2BD2MXksValtLg%3D Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5: 987–94
21. 21. M. Kobayashi H. Saitoh M. Kobayashi 2004 Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats J Pharmacol Exp Ther 309 1029 35 14978191 10.1124/jpet.103.063073 1:CAS:528:DC%2BD2cXksFCntr0%3D Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004; 309: 1029–35
22. 22. I. Neumann M. Haidinger H. Jager 2003 Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients J Am Soc Nephrol 14 721 7 12595508 10.1097/01.ASN.0000051598.12824.DA 1:CAS:528:DC%2BD3sXht1Kjt7o%3D Neumann I, Haidinger M, Jager H, et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol 2003; 14: 721–7
23. 23. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004; 50: 3418-26
24. 24. I.S. Westley B.C. Sallustio R.G. Morris 2005 Validation of a high-performance liquid chromatography method for the measurement of mycophenolic acid and its glucuronide metabolites in plasma Clin Biochem 38 824 9 15963486 10.1016/j.clinbiochem.2005.05.008 1:CAS:528:DC%2BD2MXntVGgurY%3D Westley IS, Sallustio BC, Morris RG. Validation of a high-performance liquid chromatography method for the measurement of mycophenolic acid and its glucuronide metabolites in plasma. Clin Biochem 2005; 38: 824–9
25. 25. J. Shen Z. Jiao Y.Q. Yu 2005 Quantification of total and free mycophenolic acid in human plasma by liquid chromatography with fluorescence detection J Chromatogr B Analyt Technol Biomed Life Sci 817 207 13 15686987 10.1016/j.jchromb.2004.12.005 1:CAS:528:DC%2BD2MXosF2jtA%3D%3D Shen J, Jiao Z, Yu YQ, et al. Quantification of total and free mycophenolic acid in human plasma by liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 817: 207–13
26. 26. M. Alvinerie J.F. Sutra P. Galtier 1990 Simultaneous measurement of Prednisone, prednisolone and hydrocortisone in plasma by high performance liquid chromatography Ann Biol Clin (Paris) 48 87 90 1:STN:280:DyaK3c3mtF2qtg%3D%3D Alvinerie M, Sutra JF, Galtier P, et al. Simultaneous measurement of Prednisone, prednisolone and hydrocortisone in plasma by high performance liquid chromatography. Ann Biol Clin (Paris) 1990; 48: 87–90
27. 27. J. Debord E. Risco M. Harel 2001 Application of a gamma model of absorption to oral cyclosporin Clin Pharmacokinet 40 375 82 11432538 10.2165/00003088-200140050-00004 1:CAS:528:DC%2BD3MXltV2ks7c%3D Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 2001; 40: 375–82
28. 28. J.L. Steimer A. Mallet J.L. Golmard 1984 Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixedeffect model Drug Metab Rev 15 265 92 6745083 10.3109/03602538409015066 1:STN:280:DyaL2c3mtFSisA%3D%3D Steimer JL, Mallet A, Golmard JL, et al. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixedeffect model. Drug Metab Rev 1984; 15: 265–92
29. 29. D.Z. D’Argenio 1981 Optimal sampling times for pharmacokinetic experiments J Pharmacokinet Biopharm 9 739 56 7341758 10.1007/BF01070904 D’Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9: 739–56
30. 30. K. Zucker A. Rosen A. Tsaroucha 1997 Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings Transpl Immunol 5 225 32 9402690 10.1016/S0966-3274(97)80042-1 1:CAS:528:DyaK2sXnslWqtbs%3D Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5: 225–32
31. 31. D. Cattaneo S. Merlini S. Zenoni 2005 Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation Am J Transplant 5 2937 44 16303008 10.1111/j.1600-6143.2005.01107.x 1:CAS:528:DC%2BD2MXhtlGns73M Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005; 5: 2937–44
32. 32. J. Pisupati A. Jain G. Burckart 2005 Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients J Clin Pharmacol 45 34 41 15601803 10.1177/0091270004270145 1:CAS:528:DC%2BD2MXks1SlsrY%3D Pisupati J, Jain A, Burckart G, et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005; 45: 34–41
33. 33. G. Filler M. Zimmering I. Mai 2000 Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression Pediatr Nephrol 14 100 4 10684356 10.1007/s004670050021 1:STN:280:DC%2BD3c7kvVequw%3D%3D Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000; 14: 100–4
34. 34. R.M. Hest van R.A. Mathot M.D. Pescovitz 2006 Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients J Am Soc Nephrol 17 871 80 16452491 10.1681/ASN.2005101070 van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006; 17: 871–80
35. 35. T. Gelder van L.M. Shaw 2005 The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation Transplantation 80 S244 53 16251857 10.1097/01.tp.0000186380.61251.fc van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005; 80: S244–53
36. 36. D. Cattaneo N. Perico F. Gaspari 2002 Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation Kidney Int 62 1060 7 12164891 10.1046/j.1523-1755.2002.00531.x 1:CAS:528:DC%2BD38XntFSrsL8%3D Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060–7